Compounded GLP-1 Drugs After the Shortages: What FDA Policy Means Now

For the better part of two years, compounded GLP-1 drugs filled a gap. Brand-name semaglutide and tirzepatide were in shortage, and compounding pharmacies stepped in to meet demand. Now that the national supply is stabilizing, the FDA is clarifying its enforcement policies. The shift leaves patients, prescribers, and pharmacies navigating a landscape where the legal status of compounded GLP-1 products depends heavily on whether an active shortage still exists.

Why clinicians worry

Clinician concerns about compounded GLP-1 drugs center on formulation, oversight, and patient understanding. Stanford Medicine Insights recently highlighted why doctors worry about safety when patients use compounded versions of these medications. The core issue is not that every compounded dose is contaminated or improperly prepared. Rather, it is that compounded drugs are not FDA-approved, meaning they bypass the agency's rigorous review of manufacturing quality, labeling accuracy, and clinical safety data.

Without FDA approval, there is no agency-verified confirmation that a compounded product's dosage form, strength, or route of administration matches the reference drug exactly. Patients may receive a product that differs in absorption, stability, or side-effect profile. For a drug class that can cause significant gastrointestinal effects and requires careful dose titration, those differences matter.

What FDA policy actually says

The FDA's position on compounded GLP-1 drugs has always been tied to shortage status. When a drug appears on the FDA's shortage list, section 503A and 503B compounding pharmacies can legally prepare copies of the approved product to help meet demand. When the shortage resolves, that legal basis narrows significantly.

In recent guidance, the FDA clarified its policies for compounders as the national GLP-1 supply begins to stabilize. The agency indicated it does not intend to take action against compounders for certain activities while shortages persist, but that enforcement posture changes once a drug is no longer in shortage. Patients and prescribers should understand that the availability of compounded GLP-1 products is not permanent; it is contingent on shortage status and the specific regulatory framework that applies to a given pharmacy.

Approval, formulation, and dosing

The FDA has published detailed information about medications containing semaglutide marketed for type 2 diabetes or weight loss. That resource underscores a critical distinction: FDA-approved products like Ozempic, Wegovy, and Rybelsus have passed through the agency's full review process. Compounded versions have not.

Formulation differences are a particular concern. Some compounded products have used salt forms of semaglutide, such as semaglutide sodium or semaglutide acetate, which are not the active pharmaceutical ingredient used in the FDA-approved drugs. The FDA has noted that these salt forms may have different absorption and safety characteristics. Patients should not assume that a compounded product is pharmacologically identical to its branded counterpart.

Dosing is another area where confusion arises. Compounded GLP-1 products are often sold in different concentrations or volume units than the approved pen injectors. A patient switching between an approved product and a compounded one, or moving between compounders, may encounter dosing discrepancies that increase the risk of underdosing or adverse effects.

Legal compounding versus illicit copying and counterfeits

It is important to separate legally operating compounding pharmacies from illicit operations and online counterfeits. Section 503A pharmacies operate under state oversight and must meet specific conditions, including receiving valid prescriptions for individually identified patients. Section 503B outsourcing facilities register with the FDA and are subject to current good manufacturing practice requirements.

These legal frameworks are distinct from the illicit copying of branded drugs or the sale of counterfeit GLP-1 products through unverified online channels. Counterfeit semaglutide has been documented in international supply chains and has prompted FDA warnings. Patients should not conflate a state-licensed compounding pharmacy producing a product under a valid prescription with an unregulated website selling unlabeled vials.

Material limitations

Several limitations shape how patients and prescribers should interpret the current landscape. First, the FDA's shortage list is dynamic. A drug may be added or removed as supply conditions change, which in turn affects the legal basis for compounding. Second, the agency's enforcement discretion policies are not permanent guarantees; they are time-limited guidance documents that can be revised or withdrawn.

Third, the absence of FDA approval for compounded products means that data on long-term safety, efficacy, and consistency is limited compared to the clinical trial evidence supporting branded GLP-1 drugs. Patients considering or currently using a compounded product should discuss their options with a licensed prescriber who can weigh individual circumstances, including access, cost, and safety considerations.

This article does not provide personal medical advice or dosing instructions. It is an editorial summary of publicly available regulatory and clinical information.

What patients should understand

• Compounded drugs are not FDA-approved, even when prepared legally by a licensed pharmacy.
• The legal basis for compounding GLP-1 products depends on whether the drug remains on the FDA shortage list.
• Formulation differences, including the use of salt forms, may affect how a compounded product behaves in the body.
• Dosing concentrations and units may differ from branded products, creating switching risks.
• Legal compounding under sections 503A and 503B is distinct from illicit copying and online counterfeits.

As the GLP-1 market continues to evolve, the line between access and oversight will remain contested. The FDA's stabilization of supply does not eliminate demand for lower-cost alternatives, but it does narrow the regulatory window in which compounded versions can be legally produced. Patients and prescribers should stay informed about shortage status, formulation details, and the regulatory category of any pharmacy supplying these products.